Patents by Inventor Michael Pleiss

Michael Pleiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6949570
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: September 27, 2005
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Susan Ashwell, Reinhardt Bernhard Baudy, Michael A. Pleiss, Dimitrios Sarantakis, Eugene D. Thorsett
  • Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
    Publication number: 20050203093
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Application
    Filed: January 10, 2005
    Publication date: September 15, 2005
    Inventors: Andrei Konradi, Michael Pleiss, Eugene Thorsett, Susan Ashwell, Gregory Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren Dressen, Francine Grant, Christopher Semko, Ying-Zi Xu
  • Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
    Publication number: 20050203080
    Abstract: Disclosed are compounds which inhibit ?-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits ?-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Application
    Filed: December 12, 2003
    Publication date: September 15, 2005
    Inventors: Jing Wu, Jay Tung, Eugene Thorsett, Michael Pleiss, Jeffrey Nissen, R. Neitz, Lee Latimer, Varghese John, Stephen Freedman, Thomas Britton, James Audia, Jon Reel, Thomas Mabry, Bruce Dressman, Cynthia Cwi, James Droste, Steven Henry, Stacey McDaniel, William Scott, Russell Stucky, Warren Porter
  • Anti-inflammatory compositions and method
    Patent number: 6939855
    Abstract: The disclosed invention includes pharmaceutical compositions and methods for treating inflammatory conditions, particularly those that are characterized by increased binding of alpha-9 integrin to one or more of its ligands. Also disclosed are methods for selecting compounds for use in such compositions and methods.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: September 6, 2005
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Theodore A. Yednock, Michael A. Pleiss
  • Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
    Publication number: 20050192280
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Application
    Filed: April 14, 2005
    Publication date: September 1, 2005
    Inventors: Andrei Konradi, Michael Pleiss, Eugene Thorsett, Susan Ashwell, Gregory Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren Dressen, Francine Grant, Christopher Semko, Ying-Zi Xu
  • Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
    Publication number: 20050182046
    Abstract: Disclosed are compounds which inhibit ?-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits ?-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
    Type: Application
    Filed: February 13, 2004
    Publication date: August 18, 2005
    Inventors: Jing Wu, Jay Tung, Eugene Thorsett, Michael Pleiss, Jeffrey Nissen, R. Neitz, Lee Latimer, Varghese John, Stephen Freedman, Thomas Britton, James Audia, Jon Reel, Thomas Mabry, Bruce Dressman, Cynthia Cwi, James Droste, Steven Henry, Stacey McDaniel, William Scott, Russell Stucky, Warren Porter
  • Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6911439
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: June 28, 2005
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarntakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu
  • Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
    Publication number: 20050130999
    Abstract: Disclosed are compounds which bind ?4 integrins, where the ?4 integrin is preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by ?4 integrins, where the ?4 integrin is preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Application
    Filed: May 27, 2003
    Publication date: June 16, 2005
    Inventors: Andrei Konradi, Christopher Semko, Ying-zi Xu, Frank Stappenbeck, Brian Stupi, Jenifer Smith, Michael Pleiss, Eugene Thorsett
  • Compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6903088
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, antherosclerosis. AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: June 7, 2005
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Christopher Semko, Robert Warren Sullivan, Christopher Joseph Soares, Kiev Sui Ly
  • Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
    Publication number: 20050119290
    Abstract: Disclosed are compounds which bind ?4 integrins, preferably VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by ?4 integrins, preferably VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Application
    Filed: May 27, 2003
    Publication date: June 2, 2005
    Inventors: Andrei Konradi, Christopher Semko, Ying-Zi Xu, Frank Stappenbeck, Brian Stupi, Jenifer Smith, Michael Pleiss, Eugene Thorsett
  • Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6900179
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: May 31, 2005
    Inventors: Eugene D. Thorsett, Christopher M. Semko, Dimitrios Sarantakis, Michael A. Pleiss, Anthony Kreft, Andrei W. Konradi, Francine S. Grant, Darren B. Dressen, Susan Ashwell, Reinhardt Bernhard Baudy, Louis John Lombardo
  • Alpha amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
    Publication number: 20050085459
    Abstract: Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Application
    Filed: September 7, 2004
    Publication date: April 21, 2005
    Inventors: Andrei Konradi, Michael Pleiss, Eugene Thorsett, Susan Ashwell, Gregory Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren Dressen, Francine Grant, Christopher Semko, Ying-Zi Xu
  • Methods and compositions for treating rheumatoid arthritis
    Publication number: 20050074451
    Abstract: This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha-4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin (?4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: June 25, 2004
    Publication date: April 7, 2005
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Theodore Yednock, Stephen Freedman, Ivan Lieberburg, Michael Pleiss, Andrei Konradi, George Shopp, Elizabeth Messersmith
  • Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
    Publication number: 20050069541
    Abstract: The application provides for methods and compositions for inhibiting demyelination, promoting remyelination and/or treating paralysis in a subject in need thereof. Preferably, such compositions include immunoglobulins (e.g., antibodies, antibody fragments, and recombinantly produced antibodies or fragments), polypeptides (e.g., soluble forms of the ligand proteins for integrins) and small molecules, which when administered in an effective amount inhibits demyelination and/or promotes remyelination in a patient. The compositions and methods described herein can also utilize other anti-inflammatory agents used to palliate conditions and diseases associated with demyelination.
    Type: Application
    Filed: January 26, 2004
    Publication date: March 31, 2005
    Inventors: Stephen Karlik, Michael Pleiss, Andrei Konradi, Francine Farouz, Christopher Semko, Darren Dressen, Elizabeth Messersmith, Stephen Freedman, Ted Yednock
  • Methods and compositions for treating rheumatoid arthritis
    Publication number: 20050065192
    Abstract: This application relates to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and an antibody to alpha-4 integrin or an immunologically active antigen binding fragment in therapeutically effective amounts. The application also relates generally to methods and compositions for treating rheumatoid arthritis by administering a combination therapy comprising methotrexate and small molecule alpha-4 integrin antagonist that inhibits the alpha-4 integrin (?4 integrin) interaction with VCAM-1. The invention further relates to methods of preparing the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: June 25, 2004
    Publication date: March 24, 2005
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Theodore Yednock, Stephen Freedman, Ivan Lieberburg, Michael Pleiss, Andrei Konradi, George Shopp, Elizabeth Messersmith
  • Method and apparatus for mitigating thermal pole tip protrusion
    Patent number: 6867940
    Abstract: A method of operating a transducer includes heating a write element by passing a preheat electrical current through a conductive coil of the write element in a manner which produces a substantially zero magnetic flux. The method also includes writing data to a media after heating the write element by passing a write electrical current through the conductive coil in a manner in which produces a net magnetic flux.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: March 15, 2005
    Assignee: Seagate Technology LLC
    Inventor: Curtis Michael Pleiss
  • Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
    Publication number: 20050038099
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: February 17, 2005
    Inventors: Jay Tung, Albert Garofalo, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, Jennifer Marugg, Martin Neitzel
  • Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
    Publication number: 20050032868
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: February 10, 2005
    Inventors: Albert Garofalo, Jay Tung, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, Jennifer Marugg, Martin Neitzel
  • Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
    Publication number: 20050020659
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: January 27, 2005
    Inventors: Jay Tung, Albert Garofalo, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, R. Neitz, Jennifer Marugg, Martin Neitzel
  • 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
    Publication number: 20040266763
    Abstract: Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Application
    Filed: July 23, 2004
    Publication date: December 30, 2004
    Applicants: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu, Frank Stappenbeck